Cargando…

Pancreatic cancer: Hurdles in the engineering of CAR-based immunotherapies

Pancreatic cancer remains largely an incurable disease necessitating the development of novel therapeutic approaches. Adoptive immunotherapy using chimeric antigen receptor (CAR)-transduced T cells represents an alternative treatment with curative potential. We present an overview of the engineering...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abate-Daga, Daniel, Rosenberg, Steven A, Morgan, Richard A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2014
Materias:	Author's View
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4108460/ https://www.ncbi.nlm.nih.gov/pubmed/25083334 http://dx.doi.org/10.4161/onci.29194

Ejemplares similares

Engineering Grp170-based immune modulators for cancer immunotherapy
por: Yu, Xiaofei, et al.
Publicado: (2013)

Macrophage-based immunotherapy for the treatment of pancreatic ductal adenocarcinoma
por: Beatty, Gregory L
Publicado: (2013)

Dendritic cell-based immunotherapy in ovarian cancer
por: Coosemans, An, et al.
Publicado: (2013)

Radiation and immunotherapy: Renewed allies in the war on cancer
por: Seung, Steven K., et al.
Publicado: (2012)

Roadblocks to success for RNA CARs in solid tumors
por: Singh, Nathan, et al.
Publicado: (2015)

Pharmacological DNA demethylation: Implications for cancer immunotherapy
por: Roulois, David, et al.
Publicado: (2015)

Immunotherapy of acute myeloid leukemia based on γδ T cells
por: Gertner-Dardenne, Julie, et al.
Publicado: (2012)

Cancer immunotherapy: Benefit and harm?
por: Characiejus, Dainius
Publicado: (2012)

NY-ESO-1 expression in sarcomas: A diagnostic marker and immunotherapy target
por: Lai, Jin-Ping, et al.
Publicado: (2012)

Toward the next generation of NK cell-based adoptive cancer immunotherapy
por: Ni, Jing, et al.
Publicado: (2013)

Engineered chimeric antigen receptor-expressing T cells for the treatment of pancreatic ductal adenocarcinoma
por: Beatty, Gregory L
Publicado: (2014)

Acute myeloid leukemia therapeutics: CARs in the driver’s seat
por: Mardiros, Armen, et al.
Publicado: (2013)

New insights into the role of NK cells in cancer immunotherapy
por: Salagianni, Maria, et al.
Publicado: (2012)

Discovering cancer immunotherapy targets in vivo
por: Zhou, Penghui, et al.
Publicado: (2014)

Targeting cancer stem cells with ALDH1A1-based immunotherapy
por: DeLeo, Albert B.
Publicado: (2012)

IL-21 in cancer immunotherapy: At the right place at the right time
por: Santegoets, Saskia JAM, et al.
Publicado: (2013)

Pro-survival signaling via CD27 costimulation drives effective CAR T-cell therapy
por: Song, De-Gang, et al.
Publicado: (2012)

Immunotherapy of HPV-associated head and neck cancer: Critical parameters
por: Nizard, Mevyn, et al.
Publicado: (2013)

Blockade of PD-1 immunosuppression boosts CAR T-cell therapy
por: John, Liza B, et al.
Publicado: (2013)

Arming NK cells with enhanced antitumor activity: CARs and beyond
por: Oberoi, Pranav, et al.
Publicado: (2013)

Combined targeted therapy and immunotherapy in the treatment of advanced melanoma
por: Wilmott, James S., et al.
Publicado: (2012)

Combining conventional chemotherapy and γδ T cell-based immunotherapy to target cancer-initiating cells
por: Todaro, Matilde, et al.
Publicado: (2013)

Chemokine-enhanced DNA vaccination in cancer immunotherapy
por: Igoucheva, Olga, et al.
Publicado: (2013)

Cancer cell associated glycans as targets for immunotherapy
por: Vankemmelbeke, Mireille, et al.
Publicado: (2015)

Modifying tumor-associated macrophages: An important adjunct to immunotherapy
por: Fridlender, Zvi G, et al.
Publicado: (2013)

Local immunotherapy based on agonistic CD40 antibodies effectively inhibits experimental bladder cancer
por: Sandin, Linda C, et al.
Publicado: (2014)

The immune landscape of human tumors: Implications for cancer immunotherapy
por: Bindea, Gabriela, et al.
Publicado: (2014)

FIST, a sword and shield fusokine for cancer immunotherapy
por: Penafuerte, Claudia, et al.
Publicado: (2012)

Cancer immunotherapy with exosomes requires B-cell activation
por: Näslund, Tanja I, et al.
Publicado: (2013)

Targeting dendritic cells in situ for breast cancer immunotherapy
por: Wang, Bei
Publicado: (2012)

Of microspheres and microbes: A double-hit strategy for cancer immunotherapy
por: Brinkhoff, Benjamin, et al.
Publicado: (2014)

A new role for NFκB in immunosurveillance and its implications for cancer immunotherapy
por: Beg, Amer A, et al.
Publicado: (2013)

Rewiring cancer cell death to enhance oncolytic viro-immunotherapy
por: Workenhe, Samuel T, et al.
Publicado: (2013)

A novel strategy for modulation of MDSC to enhance cancer immunotherapy
por: Ghansah, Tomar
Publicado: (2012)

Inhibition of RANK signaling as a potential immunotherapy in breast cancer
por: Gómez-Aleza, C, et al.
Publicado: (2021)

Immunotherapy: Is it different for sarcomas?
por: Cleton-Jansen, Anne-Marie, et al.
Publicado: (2012)

Long peptide-based cancer immunotherapy targeting tumor antigen-specific CD4(+) and CD8(+) T cells
por: Tomita, Yusuke, et al.
Publicado: (2013)

Overcoming intrinsic inhibitory pathways to augment the antineoplastic activity of adoptively transferred T cells: Re-tuning your CAR before hitting a rocky road
por: Wang, Liang-Chuan S, et al.
Publicado: (2013)

Importance of helper T-cell activation in dendritic cell-based anticancer immunotherapy
por: Schreibelt, Gerty, et al.
Publicado: (2013)

The immunological profile of tumor-bearing animals determines the outcome of cancer immunotherapy
por: Quetglas, José I, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ijjfqsff0fujf8vgaup7me9q6h